SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is trending as investors weigh its role as a digital silver alternative against recent volatility and long-term price performance. The community is actively discussing potential network upgrades, the impact of upcoming halving cycles, and comparisons to other major assets, while debating whether current price levels represent a significant accumulation opportunity.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following positive Phase 3 results for its hereditary angioedema therapy, despite facing volatility from a recent equity offering. While some investors are concerned about dilution, community sentiment remains heavily focused on the stock's significant short interest, with many anticipating a potential squeeze driven by the company's long-term commercialization prospects.

What makes MOG an absolute game-changer is our relentless dedication to memes and viral brilliance! We don't settle for mediocrity; we plunge into the realm of sheer awesomeness! Our community is a powerhouse of meme warriors, unleashing an unstoppable onslaught of viral memes that'll leave you in awe and stitches!  We're not here to play games; we're here to dominate! MOG is all about pushing the boundaries, smashing through barriers, and leaving our competitors eating our dust! Our passion for humor burns like an inferno, and we won't rest until the entire internet bows down to our meme supremacy!  And our community? It's a brotherhood, an unyielding powerhouse of support and camaraderie! When you're part of MOG, you're part of an unstoppable force, a family forged by the fire of meme revolution!  So, if you're ready to be part of the most intense, mind-bending memecoin movement ever conceived, then buckle up, strap in, and brace yourself! MOG is here to claim the throne, and we're taking no prisoners! Get ready to witness meme history in the making!

 MOG Coin

Mog Coin remains a highly contentious topic on social platforms, with participants intensely debating whether the asset is a viable long-term meme play or a deceptive pump-and-dump scheme. The community is actively divided, with many traders closely monitoring for potential momentum shifts or listing news, while others warn of significant volatility and structural risks.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is seeing increased engagement driven by a mix of broader crypto market momentum, technical breakout patterns, and persistent community speculation regarding its long-term potential in the data economy and AI-linked IoT sectors. While some investors remain highly optimistic about upcoming infrastructure and governance developments, others caution against volatility and remain skeptical, highlighting the ongoing divide between long-term proponents and those wary of past performance.

Schwab Strategic Trust - Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF

Schwab US Dividend Equity ETF (SCHD) is trending as investors favor its defensive stability and dividend growth amidst broader market volatility, with community members actively discussing its role as a core portfolio anchor and comparing it to high-growth tech alternatives.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as investors weigh the potential for a regulatory path following positive data from the SOL-1 trial against the uncertainty of a single-trial NDA submission and increased competition in the ophthalmology space. The community is actively debating the likelihood of a buyout versus a standalone commercialization strategy, with sentiments split between optimism for Axpaxlis market disruption and concern over management's communication regarding regulatory timelines.

The TROLL token on the Solana network is a meme coin inspired by internet trolling culture, designed for entertainment and community engagement with no intrinsic value. Built on Solana’s blockchain, it leverages the network’s fast transactions and low fees to appeal to meme enthusiasts. Launched on decentralized exchanges, TROLL aims to foster a fun, community-driven ecosystem through social media, influencer partnerships, and viral marketing, embodying the playful spirit of online trolling.

Troll

The Troll community is heavily promoting the token as an original meme with secured IP rights, positioning it as the next major multibillion-dollar runner alongside established classics. Investors are actively debating its potential for explosive growth while emphasizing the strength of its dedicated, "OG" community culture.

Analog Devices, Inc. is a semiconductor company, which engages in the combination of analog, digital, and software technologies into engineering solutions. Its products include analog and mixed signals, power management and reference, amplifiers radio frequency, and reference, sensors and actuators, and digital signal processing and system. The company was founded by Raymond P. Stata and Matthew Lorber in 1965 and is headquartered in Wilmington, MA.

Analog Devices Inc.

Analog Devices is trending as a key beneficiary of the AI infrastructure boom, with the community highlighting its essential role in power architecture and precision analog technology for high-efficiency data centers. Investors are closely monitoring the stock following strong quarterly performance and strategic moves to bolster its position in the rapidly expanding AI power and electrification market.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending as investors debate whether the current price action signals a bottoming phase or a continuation of a multi-year downtrend. While some community members highlight upcoming network upgrades and long-term tokenization potential, the conversation is dominated by intense skepticism from traders who view it as a declining asset and are actively betting against its recovery.

KAIO provides institutional-grade real-world asset (RWA) tokenization infrastructure that seamlessly connects traditional investment funds with digital capital markets. Through its purpose-built protocol, KAIO enables leading global asset managers to issue and distribute regulated tokenized funds across multiple high-performance blockchain networks — including Ethereum, Sei, Hedera, Solana, Aptos, and others — significantly expanding global access to institutional-quality real-world asset strategies for qualified investors.   By tokenizing feeder structures and shares in flagship funds, KAIO brings onchain access to proven strategies such as the BlackRock ICS US Dollar Liquidity Fund (one of the world’s largest institutional money market funds), the Brevan Howard Master Fund, Hamilton Lane’s Senior Credit Opportunities Fund (SCOPE) via the HL SCOPE Access Fund, and Laser Digital’s Laser Carry Fund (LCF), among others. These tokenized vehicles deliver secure, compliant exposure to money market, macro, private credit, and alternative strategies while unlocking new levels of programmability, composability, and 24/7 liquidity in DeFi environments.

KAIO

KAIO is drawing significant social media attention as investors speculate on a potential price reversal and track its performance among top gainers. Discussions center on the project's real-world asset narrative and the expectation that current accumulation phases will lead to upward momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADMA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the Class Period), have until August 10, 2026 to seek appointment as lead plaintiff of the...

ADMA Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against ADMA Biologics, Inc.

ADMA Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against ADMA Biologics, Inc. ADMA Stockholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Securities Class Action Lawsuit Against ADMA Biologics, Inc...

Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired ADMA Biologics, Inc. (ADMA or the Company) (NASDAQ: ADMA) securities between August 9...

Law Offices of Frank R. Cruz Encourages ADMA Biologics, Inc. (ADMA) Shareholders To Inquire About Securities Fraud Class Action

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired ADMA Biologics, Inc. (ADMA or the Company) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the Class Period). ADMA...

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ADMA Biologics, Inc. (ADMA or the Company) (NASDAQ: ADMA) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the...

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm PR Newswire NEW YORK, June 11, 2026 NEW YORK, June 11, 2026...

INVESTOR ALERT: Securities Class Action Filed Against ADMA Biologics, Inc. Investors Encouraged to Contact Kirby McInerney LLP

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ADMA Biologics, Inc. (ADMA or the Company) (NASDAQ:ADMA) securities during the period of August 9, 2024 through March 25, 2026, inclusive (the Class Period).If you suffered a...

Adma Biologics (ADMA) Stock Dips While Market Gains: Key Facts

Adma Biologics (ADMA) closed the most recent trading day at $8.33, moving 1.83% from the previous trading session.

ADMA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. (ADMA Biologics or the Company) (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action...

ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead the ADMA Biologics Class Action Lawsuit

ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead the ADMA Biologics Class Action Lawsuit ADMA INVESTOR ALERT: ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead the ADMA Biologics Class Action Lawsuit PR Newswire SAN...

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing and Plasma Collection Center. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

ADMAAdma Biologics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ADMA News